Implementation of a Nebulized Tranexamic Acid Protocol for Pediatric Post‐Tonsillectomy Hemorrhage: A Quality Improvement Initiative
Otolaryngology–Head and Neck Surgery · 2026
DOI: 10.1002/ohn.70341 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2026. Verfasst von Kyle W Singerman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA. Hauptthemen laut MEDLINE: Tranexamic Acid, Tonsillectomy, Postoperative Hemorrhage, Antifibrinolytic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
We hypothesized that initiation of a standardized nebulized TXA protocol for posttonsillectomy hemorrhage (PTH) would reduce the need for surgical control of bleeding without increasing adverse clinical outcomes.
Methods
This quality improvement project included patients under 18 years of age who presented with PTH. Preintervention data were collected between January 1, 2020, and June 30, 2022. Plan‐Do‐Study‐Act (PDSA) cycle 1, between July 1, 2022, and December 31, 2023, included patients who received nebulized TXA without a standardized protocol, based on emerging evidence supporting its use in PTH. PDSA cycle 2, between January 1, 2024, and July 13, 2025, followed the implementation of a standardized TXA protocol. Data included need for surgical control of bleeding, length of stay, transfusions, readmissions, and TXA‐related complications.
Results
A total of 501 patients were included, with a median age of 7.2 years, distributed across the preintervention group (n = 171), PDSA 1 (n = 205), and PDSA 2 (n = 125). The proportion of patients requiring surgical control of bleeding decreased with each intervention (43.9% vs 29.8% vs 15.2%, P < .0001). There were no changes in the length of stay, transfusion rates, readmissions, or TXA‐related complications.
Discussion
Across 2 PDSA cycles, we achieved a 65.4% reduction in the need for surgical control of bleeding for PTH without an increase in balancing measures, used as surrogates for unintended consequences of the interventions.
Implications for Practice
Implementation of a nebulized TXA protocol may be a safe and effective management option for PTH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA.
- Kansas City University College of Osteopathic Medicine, Kansas City, Missouri, USA.
- Department of Otolaryngology-Head and Neck Surgery, Children's Mercy Hospital, Kansas City, Missouri, USA.
- Lebanese American University School of Medicine, Byblos, Lebanon.
- Department of Health Services and Outcomes Research, Children's Mercy Hospital, Kansas City, Missouri, USA.
ORCID-Profile: Kyle W Singerman, Elie Khalifee
Zitieren
APA
Singerman, K. W., Nguyen, A., Welker, B., Khalifee, D., Dahl, J. P., Noel-MacDonnell, J. R., Tracy, M., & Khalifee, E. (2026). Implementation of a Nebulized Tranexamic Acid Protocol for Pediatric Post‐Tonsillectomy Hemorrhage: A Quality Improvement Initiative. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70341
Vancouver
Singerman KW, Nguyen A, Welker B, Khalifee D, Dahl JP, Noel-MacDonnell JR, et al. Implementation of a Nebulized Tranexamic Acid Protocol for Pediatric Post‐Tonsillectomy Hemorrhage: A Quality Improvement Initiative. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70341
BibTeX
@article{Singerman2026,
author = {Singerman, Kyle W and Nguyen, Andrea and Welker, Blake and Khalifee, Dovan and Dahl, John P and Noel-MacDonnell, Janelle R and Tracy, Meghan and Khalifee, Elie},
title = {Implementation of a Nebulized Tranexamic Acid Protocol for Pediatric Post‐Tonsillectomy Hemorrhage: A Quality Improvement Initiative},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2026},
doi = {10.1002/ohn.70341}
}
EUVIMED